Businesses had plenty of reasons to worry in the first half — from slowing economic growth to geopolitical tensions — but they looked beyond those factors to strike big deals at a record pace. Source: NYT > Business – Stephen Grocer
Drugmaker Deals Are Near Record Pace in 2019, but Investors Don’t Love Them All
A rush of transactions is transforming the industry, as blockbuster medicines lose patent protection. The latest acquisition cost AbbVie 16 percent of its share price. Source: NYT > Business – Stephen Grocer
AbbVie to Acquire Allergan, Botox’s Maker, for $63 Billion
The deal would give AbbVie a potent source of popular treatments as it faces the loss of patent protection for its best-selling drug, Humira. Source: NYT > Business – Michael J. de la Merced